Naoka Murakami, MD
Nephrology · Saint Louis, MONPI 1306108659
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $16,279 of the $23,891 with a category attached, or 68.1%. 7 manufacturers reported payments, led by Otsuka Pharmaceutical Development & Commercialization, Inc. at 37.7% of the total. Reporting peaked in 2022 at $8,580 and has fallen 97.5% since, to $211 in 2025. Among nephrology clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 14 payments — averaging $1706.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$9K
- Sanofi-aventis U.S. LLC$5K
- Calliditas Therapeutics US Inc.$5K
- Akebia Therapeutics Inc$2K
- Kyowa Kirin Co., Ltd$2K
- Chugai Pharmaceutical Co., Ltd.$2K
- plus $80 from 1 others
What the payments were for
- Consulting fees$16,27968%
- Speaking & faculty fees$7,21630%
- Food & beverage$3962%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $9,013 |
| Sanofi-aventis U.S. LLC | 2 | $5,097 |
| Calliditas Therapeutics US Inc. | 4 | $4,682 |
| Akebia Therapeutics Inc | 1 | $1,755 |
| Kyowa Kirin Co., Ltd | 1 | $1,739 |
| Chugai Pharmaceutical Co., Ltd. | 1 | $1,525 |
| Novartis | 2 | $80 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LIBTAYO$4,966
- TARPEYO$4,616
- CellCept$1,525
- THYMOGLOBULIN$131
How this compares
$23,891 in reported general payments places this provider in the 90th percentile of 253 nephrology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cinacalcet Hcl | 13 | $17,500 |
| Mycophenolic AcidMycophenolate Sodium | 25 | $3,906 |
| Valganciclovir Hcl | 11 | $1,131 |
| Sodium Chloride0.9 % Sodium Chloride | 26 | $948 |
| Labetalol Hcl | 19 | $504 |
| Rosuvastatin Calcium | 13 | $448 |
| Prednisone | 58 | $402 |
| Omeprazole | 12 | $336 |
| Nifedipine ErNifedipine | 12 | $256 |
| Carvedilol | 16 | $237 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 13 | $158 |
| Losartan Potassium | 12 | $147 |
| Amlodipine Besylate | 29 | $111 |
| Famotidine | 11 | $106 |
| Atorvastatin Calcium | 16 | $80 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Saint Louis
- Marcos RothsteinSaint Louis$350K
- Anuja JavaSaint Louis$240K
- Daniel CoyneSaint Louis$163K
- Tarek AlhamadSaint Louis$155K
- Tingting LiSaint Louis$130K
- Krista LentineSaint Louis$86K
- Rowena Delos SantosSaint Louis$30K
- Kabeya MwintshiSaint Louis$25K
- Benjamin HumphreysSaint Louis$13K
- Leslie GewinSaint Louis$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.